APA (7th ed.) Citation

E, K., I, B., A, K., E, B., SO, M., & D, J. (2023). Prospective Assessment of Otologic Adverse Events due to Teprotumumab: Preliminary Results. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 168(5), 1164. https://doi.org/10.1002/ohn.174

Chicago Style (17th ed.) Citation

E, Kay-Rivest, Belinsky I, Kozlova A, Byrd E, McMenomey SO, and Jethanamest D. "Prospective Assessment of Otologic Adverse Events Due to Teprotumumab: Preliminary Results." Otolaryngology--head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery 168, no. 5 (2023): 1164. https://doi.org/10.1002/ohn.174.

MLA (9th ed.) Citation

E, Kay-Rivest, et al. "Prospective Assessment of Otologic Adverse Events Due to Teprotumumab: Preliminary Results." Otolaryngology--head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery, vol. 168, no. 5, 2023, p. 1164, https://doi.org/10.1002/ohn.174.